Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0022568 (
keratitis
)
5,133
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
N6-methyladenosine (m
6
A) is the most common post-transcriptional modification of RNA in eukaryotes that regulates the post-transcriptional expression level of genes without changing the base sequence. The role of m
6
A in fungal
keratitis
has not yet been elucidated. Here, we aimed to identify m
6
A modification changes and their potential roles in fungal
keratitis
. The murine model of fungal
keratitis
was established by inoculating mice with Fusarium solani (F. solani). The overall m
6
A level was detected via an m
6
A RNA methylation assay kit. The expression levels of key m
6
A modification-related genes were estimated by quantitative real-time polymerase chain reaction (PCR). The expression and localization of METTL (methyltransferase like)3, the key component of the m
6
A methyltransferase complex, was determined by immunostaining and Western blotting (WB). Immunoprecipitation methylation microarray was used to describe the changes in m
6
A modification in F. solani-infected corneal tissue. The overall m
6
A level in corneal tissue on the 5th day in the F. solani-treated group was upregulated compared with that in the control group. The demethylase levels were unaltered, but the level of the methylase
METTL3
was increased significantly after fungal infection. Additionally, differences were found in m
6
A modifications in 1137 mRNAs, of which 780 were hypermethylated and 357 were hypomethylated. To the best of our knowledge, the present work is the first investigation on the m
6
A modification profiles in experimental fungal
keratitis
, and it may provide a potential therapeutic target.
...
PMID:Fusarium infection alters the m
6
A-modified transcript landscape in the cornea. 3289 Apr 82
